016580.KO Whanin Pharm
- Market cap
- KRW 200B
- P/E
- 9.8x
- P/B
- 0.47x
- ROE
- 7.1%
- Dividend yield
- 2.29%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 016580.KO undervalued?
Graham number016580.KO trades 54.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Whanin Pharm fundamental analysis
No fundamental analysis for Whanin Pharm yet.
Whanin Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, antiseizure, antidepressant, antipsychotic, central nervous system stimulant, anti…
Full company profileWhanin Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Whanin Pharm annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 141B | 148B | 155B | 159B | 172B | 178B | 199B | 230B | 260B | 255B | 285B |
| Gross Profit | 69.3B | 78.8B | 79.3B | 79.2B | 86.6B | 93.5B | 98.8B | 99.2B | 93.8B | 87.1B | 108B |
| Operating Income | 21.6B | 29.7B | 27.3B | 26.2B | 28.4B | 31.3B | 29.8B | 30.2B | 21.5B | 13.0B | 34.6B |
| EBITDA | - | 31.9B | 30.2B | 32.1B | 35.2B | 38.1B | 34.7B | 40.5B | 35.4B | 24.8B | 49.4B |
| Net Income | 16.4B | 27.2B | 21.5B | 18.7B | 23.4B | 26.7B | 23.9B | 29.8B | 23.4B | 13.6B | 30.3B |
| EPS | - | 1,780 | 1,409 | 1,225 | 1,532 | 1,746 | 1,567 | 1,950 | 1,531 | 836 | 1,641 |
| Balance Sheet | |||||||||||
| Total Assets | 243B | 275B | 288B | 305B | 330B | 353B | 369B | 401B | 425B | 479B | 483B |
| Total Liabilities | 23.3B | 31.8B | 28.1B | 30.4B | 33.0B | 36.0B | 35.4B | 43.0B | 48.7B | 57.9B | 57.2B |
| Shareholders' Equity | 220B | 243B | 260B | 274B | 296B | 317B | 334B | 358B | 376B | 421B | 425B |
| Cash & Short-term Investments | 57.8B | 39.9B | 38.5B | 18.0B | 36.1B | 64.1B | 36.8B | 45.4B | 43.1B | 63.6B | 56.6B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.8B | 23.5B | 17.5B | 24.7B | 22.8B | 35.3B | 16.9B | 23.2B | 20.7B | 9.04B | 20.5B |
| Capital Expenditure | 7.46B | 19.3B | 4.10B | 2.76B | 7.99B | 4.39B | 33.6B | 31.5B | 29.4B | 6.18B | 3.27B |
| Free Cash Flow | - | 4.17B | 12.9B | 21.7B | 14.5B | 30.6B | -50.9B | -8.29B | -8.69B | 2.86B | 17.2B |
| Ratios | |||||||||||
| ROE | 7.4% | 11.2% | 8.3% | 6.8% | 7.9% | 8.4% | 7.2% | 8.3% | 6.2% | 3.2% | 7.1% |
| ROA | 6.7% | 9.9% | 7.5% | 6.1% | 7.1% | 7.5% | 6.5% | 7.4% | 5.5% | 2.8% | 6.3% |
| Net Profit Margin | 11.6% | 18.4% | 13.9% | 11.7% | 13.6% | 15.0% | 12.0% | 12.9% | 9.0% | 5.3% | 10.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Whanin Pharm dividends
- Dividend yield
- 2.29%
- Forward dividend
- 300.00 KRW
- Payout ratio
- 33.7%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 4.58B | 282 | 33.7% |
| 2024 | KRW 4.58B | 300 | 19.6% |
| 2023 | KRW 4.58B | 300 | 15.4% |
| 2022 | KRW 4.58B | 300 | 19.1% |
| 2021 | KRW 4.58B | 300 | 17.2% |
| 2020 | KRW 4.58B | 300 | 19.6% |
| 2019 | KRW 4.58B | 300 | 24.5% |
| 2018 | KRW 4.58B | 300 | 21.3% |
| 2017 | KRW 3.82B | 250 | 14.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Apr 14, 2010.
Who owns Whanin Pharm
- Insiders 23.28%
- Institutions 12.01%
- Public & others 64.71%
- Shares outstanding 18.5M
- Free float 14.2M
Whanin Pharm company profile
- Company name
- Whanin Pharm
- Ticker
- 016580.KO
- ISIN
- KR7016580003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 631
- Fiscal year end
- December
- Address
- Whanin Building, 11, Seoul, South Korea, 05855
- Phone
- 82 2 405 3000
- Website
- whanin.com
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, antiseizure, antidepressant, antipsychotic, central nervous system stimulant, anti-dementia, nootropic, alcohol use disorder, anti-Parkinson, multivitamin, external preparation, medical device, and sedative, hypnotic, and autonomic nervous system medications. The company was founded in 1978 and is headquartered in Seoul, South Korea.
Whanin Pharm management
3- Mr. Kwang-Sik LeeFounder & Chairman · born 1947
- Mr. Wonbum LeeCEO, President & Director · born 1974
- Mr. JeongBae GongExecutive Director & GM of Sales · born 1975